Phase I study of DMP 840 in pediatric patients with refractory solid tumors.

Abstract

The bis-naphthalimide DMP 840 has demonstrated high level antitumor activity in a number of preclinical models and has been evaluated in several Phase I studies in adults. We enrolled 10 patients with refractory pediatric solid tumors to this Phase I study of DMP 840 given intravenously by short infusion daily for 5 days. The most frequent and dose-limiting toxicity was myelosuppression. The maximum tolerated dose on this schedule was 8.6 mg/m2 daily for 5 days. One patient had a complete response; there were no measurable tumor responses among the remaining 9 patients.

• Authors: J Thompson, C B Pratt, C F Stewart, L Avery, L Bowman, W C Zamboni, A Pappo
• Journal: Investigational new drugs (Invest New Drugs) Vol. 16 Issue 1 Pg. 45-9 ( 1998) ISSN: 0167-6997 [Print] United States
• PMID: 9740543 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Isoquinolines
• Mesylates
• bisnafide

Topics

• Adolescent
• Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
• Child
• Child, Preschool
• Humans
• Isoquinolines (administration & dosage, adverse effects, therapeutic use)
• Mesylates (administration & dosage, adverse effects, therapeutic use)
• Neoplasms (drug therapy)
• Thrombocytopenia (chemically induced)
• Treatment Outcome